NCT00505973
Completed
Phase 1
An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SCA-136 Administered Orally to Healthy Japanese Male Subjects
Wyeth is now a wholly owned subsidiary of Pfizer0 sites24 target enrollmentJuly 2007
ConditionsSchizophrenia
DrugsSCA-136
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Schizophrenia
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Enrollment
- 24
- Primary Endpoint
- Adverse events, safety laboratory results, vital signs, and ECGs will be used to monitor subject safety.
- Status
- Completed
- Last Updated
- 18 years ago
Overview
Brief Summary
This study is being conducted to assess the safety and tolerability of ascending multiple oral doses of SCA-136 administered to healthy Japanese male subjects.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Adverse events, safety laboratory results, vital signs, and ECGs will be used to monitor subject safety.
Similar Trials
Completed
Phase 1
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female SubjectsSchizophreniaNCT00458107Wyeth is now a wholly owned subsidiary of Pfizer64
Completed
Phase 1
Study Evaluating the Pharmacokinetics of HCV-796 in Healthy Japanese MenHealthyNCT00385190Wyeth is now a wholly owned subsidiary of Pfizer24
Completed
Phase 1
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With SchizophreniaSchizophreniaNCT02720263Astellas Pharma Global Development, Inc.48
Completed
Phase 1
Multiple Rising Oral Dose Study of PG 760564 Administered Twice Daily to Healthy Male/Female Volunteers for 14 DaysHealthyNCT00791388Procter and Gamble45
Completed
Phase 1
Study Evaluating Multiple Oral Doses of PPM-204 in Healthy Japanese Male SubjectsDiabetes MellitusNCT00448032Wyeth is now a wholly owned subsidiary of Pfizer